SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Hikal - Quaterly Results

29 May 2023 Evaluate
The revenue zoomed 8.55% to Rs. 5452.90 millions for the quarter ended March 2023 as compared to Rs. 5023.50 millions during the corresponding quarter last year.Net profit for the quarter ended March 2023 increased significantly by 73.75% to Rs. 360.70 millions from Rs. 207.60 millions.The company reported a good operating profit of 884.60 millions compared to 613.10 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202303 202203 % Var 202303 202203 % Var 202303 202203 % Var
Sales 5452.90 5023.50 8.55 20230.30 19427.20 4.13 20230.30 19427.20 4.13
Other Income 3.80 2.70 40.74 54.10 48.90 10.63 54.10 48.90 10.63
PBIDT 884.60 613.10 44.28 2624.70 3454.50 -24.02 2624.70 3454.50 -24.02
Interest 129.80 80.80 60.64 481.00 312.10 54.12 481.00 312.10 54.12
PBDT 754.80 532.30 41.80 2143.70 3142.40 -31.78 2143.70 3142.40 -31.78
Depreciation 268.30 242.30 10.73 1090.10 956.70 13.94 1090.10 956.70 13.94
PBT 486.50 290.00 67.76 1053.60 2185.70 -51.80 1053.60 2185.70 -51.80
TAX 125.80 82.40 52.67 269.80 580.60 -53.53 269.80 580.60 -53.53
Deferred Tax -21.20 4.40 -581.82 -35.00 -15.90 120.13 -35.00 -15.90 120.13
PAT 360.70 207.60 73.75 783.80 1605.10 -51.17 783.80 1605.10 -51.17
Equity 246.60 246.60 0.00 246.60 246.60 0.00 246.60 246.60 0.00
PBIDTM(%) 16.22 12.20 32.92 12.97 17.78 -27.04 12.97 17.78 -27.04

Hikal Share Price

192.15 3.60 (1.91%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×